Peptides and Epilepsy: Seizure-Related Research

Epilepsy: More Than Just Seizures

Epilepsy is a chronic neurological disorder characterized by recurrent, unprovoked seizures. But the disease burden extends beyond seizure events themselves. Chronic neuroinflammation, oxidative stress, and neurotoxic glutamate release between seizures contribute to progressive cognitive decline and increased seizure susceptibility (epileptogenesis). Roughly one-third of people with epilepsy do not achieve seizure control with available medications, driving research into alternative mechanisms.

Selank and GABAergic Modulation

Selank is a synthetic analogue of tuftsin with well-documented anxiolytic properties. Its mechanism involves modulation of the GABA-A receptor system — the same receptor family targeted by benzodiazepines and many anticonvulsants. In animal models, Selank has shown anti-anxiety and calming effects without the sedation or tolerance issues associated with benzodiazepines. Some researchers have proposed it as a candidate for investigation in anxiety-related seizure thresholds, given the tight relationship between GABAergic tone and seizure susceptibility.

View Selank →

Semax and Neuroprotection After Seizures

Seizure activity generates significant oxidative stress and excitotoxic glutamate release, which can damage neurons even between clinical seizures. Semax’s ability to upregulate BDNF and activate antioxidant pathways positions it as a potential neuroprotective agent for the inter-ictal period — the time between seizures when neuronal damage from prior events can accumulate. In ischemic and excitotoxic rodent models, Semax has consistently reduced neuronal apoptosis markers and preserved cognitive function outcomes, endpoints relevant to epilepsy-associated cognitive decline.

View Semax →

DSIP (Delta Sleep-Inducing Peptide) and Seizure Research

DSIP (delta sleep-inducing peptide) was first identified for its sleep-promoting properties but has since been studied for anticonvulsant effects in animal models. Early Soviet-era research found DSIP reduced seizure frequency in pentylenetetrazol (PTZ) and other chemically-induced epilepsy models in rodents. DSIP appears to modulate opioid receptors and limbic system activity, though its anticonvulsant mechanism is not fully characterized. Interest in DSIP for epilepsy research has been limited by poor bioavailability and short plasma half-life.

Glutamate Excitotoxicity: A Common Thread

Many peptides studied in epilepsy research share a common theme: reducing glutamate excitotoxicity. During seizures, massive glutamate release overwhelms AMPA and NMDA receptors, triggering a calcium influx that can kill neurons. BPC-157 and Semax have both shown glutamate-modulating effects in preclinical models, adding them to the list of peptides with theoretical relevance to post-seizure neuroprotection research.

Neuroinflammation and Epileptogenesis

A growing body of research shows that IL-1β, TNF-α, and other inflammatory cytokines lower seizure threshold and promote epileptogenesis. Peptides with anti-inflammatory profiles — including Selank and Semax — are therefore theoretically relevant not just to seizure management but to prevention of progression in newly diagnosed epilepsy models. This is an active area of preclinical investigation.

Research Limitations

Epilepsy is a heterogeneous condition with dozens of distinct syndromes and etiologies. A compound that reduces seizures in a chemically-induced rodent model may have no effect in a genetic epilepsy model, let alone in human focal epilepsy. None of the peptides discussed here have undergone epilepsy-specific human clinical trials. They represent mechanistic leads for research, not clinical interventions.

Written by the NorthPeptide Research Team

References